Antipsychotic prescribing patterns in a Medicare Advantage population of older individuals with dementia

References

• Alexopoulous G, Streim J, Carpenter D, Docherty J. (2004). Using antipsychotic agents in older patients: Introduction. J Clin Psychiatry, 65, 1–105
   Web of Science ®Google Scholar
• American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders. 5th ed. Washington (DC): American Psychiatric Association
   Google Scholar
• Ballard C, Waite J. (2006). The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer’s disease. Cochrane Database Syst Rev, (1), CD003476
   PubMedGoogle Scholar
• Brodaty H, Ames D, Snowdon J, et al. (2003). A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry, 64, 134–43
   PubMed Web of Science ®Google Scholar
• Center for Medicare and Medicaid Services. (2015). Available from: http://www.cms.gov [last accessed 20 Feb 2015]
   Google Scholar
• Connell CM, Janevic MR, Gallant MP. (2001). The costs of caring: Impact of dementia on family caregivers. J Geriatr Psychiatry Neurol, 14, 179–87
   PubMed Web of Science ®Google Scholar
• Deberdt WG, Dysken MW, Rappaport SA, et al. (2005). Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia. Am J Geriatr Psychiatry, 13, 722–30
   PubMed Web of Science ®Google Scholar
• Eichler T, Wucherer D, Thyrian JR, et al. (2015). Antipsychotic drug treatment in ambulatory dementia care: Prevalence and correlates. J Alzheimers Dis, 43, 1303–11
   PubMed Web of Science ®Google Scholar
• Gareri P, Fazio PD, Manfredi VG, Sarro GD. (2014). Use and safety of antipsychotics in behavioral disorders in elderly people with dementia. J Clin Psychopharmacol, 34, 109–23
   PubMed Web of Science ®Google Scholar
• Guthrie B, Clark S, McCowan C. (2010). The burden of psychotropic drug prescribing in people with dementia: A population database study Age Ageing, 39, 637–42
   PubMed Web of Science ®Google Scholar
• Huang H, Chan YF, Bauer AM, et al. (2013a). Specialty behavioral health service use among chronically ill medicare advantage patients with substance use problems. Psychosomatics, 54, 546–51
   PubMed Web of Science ®Google Scholar
• Huang H, Goren JL, Chan YF, et al. (2014). Pharmacologic management of bipolar disorder in a Medicare Advantage population. Psychosomatics, 55, 572–7
   PubMed Web of Science ®Google Scholar
• Huang H, Russo J, Bauer AM, et al. (2013b). Depression care and treatment in a chronically ill Medicare population. Gen Hosp Psychiatry, 35, 382–6
   PubMed Web of Science ®Google Scholar
• Kamble P, Chen H, Sherer JT, Aparasu R. (2009). Use of antipsychotics among elderly nursing home residents with dementia in the US: An analysis of National Survey Data. Drugs Aging, 26, 483–92
   PubMed Web of Science ®Google Scholar
• Katz IR, Jeste DV, Mintzer JE, et al. (1999). Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: A randomized, double-blind trial. J Clin Psychiatry, 60, 107–15
   PubMed Web of Science ®Google Scholar
• Kennedy J, Deberdt W, Siegal A, et al. (2005). Olanzapine does not enhance cognition in non-agitated and non-psychotic patients with mild to moderate Alzheimer’s dementia. Int J Geriatr Psychiatry, 20, 1020–7
   PubMed Web of Science ®Google Scholar
• Li P, Kim MM, Doshi JA. (2010). Comparison of the performance of the CMS Hierarchical Condition Category (CMS-HCC) risk adjuster with the Charlson and Elixhauser comorbidity measures in predicting mortality. BMC Health Serv Res, 10, 245
   PubMed Web of Science ®Google Scholar
• Lied T, Haffer S. (2004). Health status of dually eligible beneficiaries in managed care plans. Health Care Financ Rev, 25, 59–74
   PubMedGoogle Scholar
• Olsin D. (2000). Alcohol use in late life: Disability and comorbidity. J Geriatr Psychiatry Neurol, 13, 134–40
   PubMed Web of Science ®Google Scholar
• Pope G, Kautter J, Ellis R, et al. (2004). Risk adjustment of Medicare capitation payments using the CMS-HCC model. Health Care Financ Rev, 24, 119–41
   Google Scholar
• Puyat J, Law M, Wong S, et al. (2012). The essential and potentially inappropriate use of antipsychotics across income groups: An analysis of linked administrative data. Can J Psychiatry, 57, 488–95
   PubMed Web of Science ®Google Scholar
• Rhee Y, Csernansky JG, Emanuel LL, et al. (2011). Psychotropic medication burden and factors associated with antipsychotic use: An analysis of a population-based sample of community-dwelling older persons with dementia. J Am Geriatr Soc, 59, 2100–7
   PubMed Web of Science ®Google Scholar
• Ryan J, Super N. (2003). Dually eligible for Medicare and Medicaid: Two for one or double jeopardy? Issue Brief Natl Health Policy Forum, 794, 1–24
   Google Scholar
• Salzman C, Jeste D, Meyer RE, et al. (2008). Elderly patients with dementia-related symptoms of severe agitation and aggression: Consensus statement on treatment options, clinical trials methodology, and policy. J Clin Psychiatry, 69, 889–98
   PubMed Web of Science ®Google Scholar
• Sultzer DL. (2004). Psychosis and antipsychotic medications in Alzheimer’s disease: Clinical management and research perspectives. Dement Geriatr Cogn Disord, 17, 78–90
   PubMed Web of Science ®Google Scholar
• Unützer J, Katon W, Callahan CM, et al. (2002). Collaborative care management of late-life depression in the primary care setting: A randomized controlled trial. JAMA, 288, 2836–45
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. (2008). Information for healthcare professionals: Conventional antipsychotics. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124830.htm [last accessed 28 Jan 2015]
   Google Scholar
• US Government Accountability Office. (2015). Antipsychotic drug use. Report to congressional requesters. Washington, DC: U.S. Government
   Google Scholar
• World Health Organization. (2012). Dementia: A public health priority. Available from: http://www.who.int/mental_health/publications/dementia_report_2012 [last accessed Dec 2015]
   Google Scholar
• Zheng L, Mack W, Dagerman K, et al. (2009). Metabolic changes associated with second-generation antipsychotic use in Alzheimer’s disease patients: The CATIE-AD study. Am J Psychiatry, 166, 583–90
   PubMed Web of Science ®Google Scholar